XML 45 R35.htm IDEA: XBRL DOCUMENT v3.25.2
Segment information - Significant Segment Expenses (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Indirect research and development expenses:        
Total research and development expenses $ 7,953 $ 11,662 $ 16,243 $ 22,787
Research and Development of Immunotherapies and Vaccines        
Direct research and development expenses:        
Total direct research and development expenses 4,710 6,438 8,202 12,277
Change in direct research and development expenses (1,728)   (4,075)  
Indirect research and development expenses:        
Total indirect research and development expenses 3,243 5,224 8,041 10,510
Change In indirect research and development expenses (1,981)   (2,469)  
Total research and development expenses 7,953 11,662 16,243 22,787
Change in research and development expenses (3,709)   (6,544)  
Research and Development of Immunotherapies and Vaccines | Personnel-related (including share-based compensation)        
Indirect research and development expenses:        
Total indirect research and development expenses 2,450 4,763 6,394 9,097
Change In indirect research and development expenses (2,313)   (2,703)  
Research and Development of Immunotherapies and Vaccines | Facility related        
Indirect research and development expenses:        
Total indirect research and development expenses 350 342 685 732
Change In indirect research and development expenses 8   (47)  
Research and Development of Immunotherapies and Vaccines | Other indirect costs        
Indirect research and development expenses:        
Total indirect research and development expenses 443 119 962 681
Change In indirect research and development expenses 324   281  
Research and Development of Immunotherapies and Vaccines | VTP-1000 Celiac        
Direct research and development expenses:        
Total direct research and development expenses 1,782 1,371 2,764 2,744
Change in direct research and development expenses 411   20  
Research and Development of Immunotherapies and Vaccines | VTP-300 HBV        
Direct research and development expenses:        
Total direct research and development expenses 1,837 3,034 3,187 4,947
Change in direct research and development expenses (1,197)   (1,760)  
Research and Development of Immunotherapies and Vaccines | Other clinical programs        
Direct research and development expenses:        
Total direct research and development expenses 642 1,125 1,383 2,893
Change in direct research and development expenses (483)   (1,510)  
Research and Development of Immunotherapies and Vaccines | Other pre-clinical programs        
Direct research and development expenses:        
Total direct research and development expenses 449 908 868 1,693
Change in direct research and development expenses (459)   (825)  
Research and Development of Immunotherapies and Vaccines | VTP-500 MERS | Personnel-related (including share-based compensation)        
Indirect research and development expenses:        
Total indirect research and development expenses $ 100 $ 200 $ 100 $ 300